Drug intelligence / Profile preview

anti-interleukin-12

Development stage: Unknown
Lead developer: Abbott
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Anti-interleukin-12 is a recombinant, human-sequence, full-length IgG1 lambda monoclonal antibody developed by Wyeth Research and Abbott Laboratories. It is genetically modified to recognize the p40 subunit, which is shared by both interleukin-12 and interleukin-23. By targeting this subunit, the antibody inhibits Th1-mediated inflammatory responses. It has been investigated for the treatment of active Crohn's disease.

Targets

IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on anti-interleukin-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-interleukin-12.

Explore the full profile